BAJAJ BROKING

Notification
No new Notification messages
Wagons Learning IPO is Open!
Apply for the Wagons Learning IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

8259

208578

MADHAVBAUG

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

VAIDYA SANE AYUR LAB LTD performance

Today’s low

Today’s high

₹ 125.00 ₹ 128.00
₹ 125.00

52 week low

52 week high

₹ 81.10 ₹ 200.00
₹ 125.00

Open Price

₹ 126.95

Prev. Close

₹ 131.00

Volume (Shares)

2000.00

Total traded value

₹ 2.50

Upper Circuit

₹ 157.20

Lower Circuit

₹ 104.80

info

VAIDYA SANE AYUR LAB LTD Share Price Update

As of the latest trading session, VAIDYA SANE AYUR LAB LTD share price is currently at ₹ 125, which is down by ₹ -6.00 from its previous closing. Today, the stock has fluctuated between ₹ 125.00 and ₹ 128.00. Over the past year, VAIDYA SANE AYUR LAB LTD has achieved a return of -36.82 %. In the last month alone, the return has been 28.07 %. Read More...

VAIDYA SANE AYUR LAB LTD fundamentals


  • Market cap (Cr)

    131.41

  • P/E Ratio (TTM)

    126.26

  • Beta

    0.63

  • Book Value / share

    39.56

  • Return on equity

    1.88%

  • EPS (TTM)

    0.85

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    0.00

info icon alternate text
  • Market cap (Cr)

    0.0

  • P/E Ratio (TTM)

    0.0

  • Beta

    0.0

  • Book Value / share

    0.0

  • Return on equity

    0.0%

  • EPS (TTM)

    0.0

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    0.0

info icon alternate text

VAIDYA SANE AYUR LAB LTD Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars MAR 2024 (Values in Cr)
Revenue 97.33
Operating Expense 97.44
Net Profit 1.05
Net Profit Margin (%) 1.07
Earnings Per Share (EPS) 0.99
EBITDA 4.72
Effective Tax Rate (%) 28.27
Particulars MAR 2023 (Values in Cr)
Revenue 99.03
Operating Expense 93.48
Net Profit 5.19
Net Profit Margin (%) 5.24
Earnings Per Share (EPS) 4.94
EBITDA 9.70
Effective Tax Rate (%) 24.89
Particulars MAR 2022 (Values in Cr)
Revenue 74.71
Operating Expense 70.30
Net Profit 3.47
Net Profit Margin (%) 4.64
Earnings Per Share (EPS) 8.00
EBITDA 7.24
Effective Tax Rate (%) 26.94
Particulars MAR 2021 (Values in Cr)
Revenue 52.27
Operating Expense 50.76
Net Profit 0.39
Net Profit Margin (%) 0.74
Earnings Per Share (EPS) 87.11
EBITDA 3.20
Effective Tax Rate (%) 13.33
Particulars MAR 2020 (Values in Cr)
Revenue 75.23
Operating Expense 75.75
Net Profit -0.56
Net Profit Margin (%) -0.74
Earnings Per Share (EPS) -123.82
EBITDA 2.71
Effective Tax Rate (%) -24.44
Particulars MAR 2024 (Values in Cr)
Book Value / Share 40.11
ROE % 3.64
ROCE % 7.20
Total Debt to Total Equity 0.02
EBITDA Margin 6.83
Particulars MAR 2023 (Values in Cr)
Book Value / Share 38.48
ROE % 11.94
ROCE % 17.30
Total Debt to Total Equity 0.00
EBITDA Margin 9.97
Particulars MAR 2024 (Values in Cr)
Book Value / Share 39.56
ROE % 1.88
ROCE % 4.70
Total Debt to Total Equity 0.02
EBITDA Margin 5.53
Particulars MAR 2023 (Values in Cr)
Book Value / Share 38.82
ROE % 13.54
ROCE % 19.16
Total Debt to Total Equity 0.02
EBITDA Margin 10.46
Particulars MAR 2022 (Values in Cr)
Book Value / Share 34.13
ROE % 15.20
ROCE % 20.93
Total Debt to Total Equity 0.05
EBITDA Margin 10.25
Particulars MAR 2021 (Values in Cr)
Book Value / Share 2170.44
ROE % 10.34
ROCE % 14.76
Total Debt to Total Equity 0.39
EBITDA Margin 8.74
Particulars MAR 2020 (Values in Cr)
Book Value / Share 1826.64
ROE % -6.58
ROCE % 4.44
Total Debt to Total Equity 0.86
EBITDA Margin 3.96
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 17.14
Total Assets 70.89
Total Liabilities 70.89
Total Equity 55.60
Share Outstanding 10513450
Price to Book Ratio 4.40
Return on Assets (%) 2.79
Return on Capital (%) 3.46
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 1.76
Total Assets 54.88
Total Liabilities 54.88
Total Equity 40.45
Share Outstanding 10513450
Price to Book Ratio 6.05
Return on Assets (%) 8.80
Return on Capital (%) 11.91
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 15.95
Total Assets 71.39
Total Liabilities 71.39
Total Equity 55.02
Share Outstanding 10513450
Price to Book Ratio 4.40
Return on Assets (%) 1.46
Return on Capital (%) 1.84
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 1.75
Total Assets 55.27
Total Liabilities 55.27
Total Equity 40.80
Share Outstanding 10513450
Price to Book Ratio 6.05
Return on Assets (%) 9.38
Return on Capital (%) 12.68
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2.56
Total Assets 50.00
Total Liabilities 50.00
Total Equity 35.88
Share Outstanding 10513450
Price to Book Ratio 5.71
Return on Assets (%) 6.93
Return on Capital (%) 9.39
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 0.90
Total Assets 25.80
Total Liabilities 25.80
Total Equity 9.76
Share Outstanding 45000
Price to Book Ratio 0.00
Return on Assets (%) 1.51
Return on Capital (%) 3.64
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 1.06
Total Assets 29.11
Total Liabilities 29.11
Total Equity 8.21
Share Outstanding 45000
Price to Book Ratio 0.00
Return on Assets (%) -1.91
Return on Capital (%) -3.93
Particulars MAR 2024 (Values in Cr)
Net Income 2.86
Cash from Operations -3.42
Cash from Investing 1.49
Cash from Financing 14.46
Net change in Cash 11.54
Free Cash Flow 7.71
Particulars MAR 2023 (Values in Cr)
Net Income 6.43
Cash from Operations 2.68
Cash from Investing 0.51
Cash from Financing -1.37
Net change in Cash -0.79
Free Cash Flow 9.66
Particulars MAR 2024 (Values in Cr)
Net Income 1.45
Cash from Operations -2.46
Cash from Investing 0.01
Cash from Financing 14.46
Net change in Cash 11.37
Free Cash Flow 2.61
Particulars MAR 2023 (Values in Cr)
Net Income 6.91
Cash from Operations 2.19
Cash from Investing 0.99
Cash from Financing -1.37
Net change in Cash -0.80
Free Cash Flow 9.17
Particulars MAR 2022 (Values in Cr)
Net Income 4.74
Cash from Operations -12.12
Cash from Investing -7.52
Cash from Financing 22.49
Net change in Cash 1.65
Free Cash Flow -8.95
Particulars MAR 2021 (Values in Cr)
Net Income 1.60
Cash from Operations 6.38
Cash from Investing -0.66
Cash from Financing -5.25
Net change in Cash -0.15
Free Cash Flow 7.29
Particulars MAR 2020 (Values in Cr)
Net Income -0.44
Cash from Operations 7.91
Cash from Investing -3.93
Cash from Financing -3.63
Net change in Cash 0.15
Free Cash Flow 11.76
Company Name Price P/E P/B Market Cap 52 Week Low/High
APOLLO HOSPITALS ENTER. L 6962.05 76.41 13.35 100103.60 5690.80 / 7545.10
FORTIS MALAR HOSPITALS LIMITED 75.38 183.85 4.73 141.28 51.01 / 98.70
SHREE PACETRONIX LTD. 70.00 14.58 1.87 25.20 61.11 / 268.50
TRANSGENE BIOTEK LTD. 3.68 0.00 2.57 27.88 3.22 / 10.84
Company Name Price P/E P/B Market Cap 52 Week Low/High
APOLLO HOSPITALS ENTER. L 6962.05 83.30 12.22 100103.60 5690.80 / 7545.10
Surlux Diagnostic Ltd 1.40 0.84 0.13 0.49 0.00 / 0.00
CHENNAI MEENAKSHI MULTISPECIAL 32.25 0.00 -17.27 24.09 28.34 / 59.90
KOVAI MEDICAL CENTER & HOSPITA 5560.50 29.47 6.24 6083.19 3750.00 / 6400.00

VAIDYA SANE AYUR LAB LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
125.00 -4.58 redarrow
red-green-graph indicator
7 Bearish
9 Bullish
  • 5 Days 130.60
  • 26 Days 117.30
  • 10 Days 126.90
  • 50 Days 115.50
  • 12 Days 125.10
  • 100 Days 121.40
  • 20 Days 119.60
  • 200 Days 138.20
132.33 PIVOT

First Support

128.92

First Resistance

134.42

Second Support

126.83

Second Resistance

137.83

Third Support

123.42

Third Resistance

139.92

RSI

55.99

ADX

25.98

MACD

7.81

Williams % R

-41.42

Commodity Channel Index (CCI)

58.95

Date

2025-04-30

Week

7667.00

Same Day

1200.00

Month

5765.00

1 Year

0.63

3 Year

0.56

Over 1 Month

28.07%

down

Over 1 Year

-36.82%

down

Over 3 Months

0.40%

down

Over 3 Years

-12.64%

down

Over 6 Months

-10.00%

down

Over 5 Years

0.00%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

VAIDYA SANE AYUR LAB LTD shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
33.66%
Promoter Holdings
66.33%
FII
0.0%
DII
0.0%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Rohit Madhav Sane 6969300.0 (66.29%) Shareholding of Promoter and Promoter Group
Virtuous Capital Limited 523124.0 (4.98%) Public Shareholding
Dharmesh C Patel 417200.0 (3.97%) Public Shareholding
Thermo Pads Private Limited 234800.0 (2.23%) Public Shareholding
Santosh Gopalkrishna Kudva 183963.0 (1.75%) Public Shareholding
Vinayak G Kudva 130363.0 (1.24%) Public Shareholding
Rekha Jitesh Paralkar . 5000.0 (0.05%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

VAIDYA SANE AYUR LAB LTD corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
05 Sep 2023 0.25 Final 06 Sep 2023 Equity shares
18 Nov 2022 0.25 Interim 18 Nov 2022 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
05 Sep 2023 0.25 Final 06 Sep 2023 Equity shares
18 Nov 2022 0.25 Interim 18 Nov 2022 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

VAIDYA SANE AYUR LAB LTD Share Price

Vaidya Sane Ayurved Laboratories Limited was originally incorporated as a Private Limited Company pursuant to a Certificate of Incorporation issued by the Registrar of Companies, Pune dated April 6, 1999 with the name Vaidya Sane Ayurved Laboratories Private Limited'. Subsequently, Company was converted into to a Public Limited Company and the name of Company was changed to Vaidya Sane Ayurved Laboratories Limited'. A fresh Certificate of Incorporation upon conversion was issued on November 25, 2021 by the Registrar of Companies, Pune. Dr. Rohit Madhav Sane is the Present Promoter of the Company.

The Company is a unique medical service institution that strives to treat chronic ailments like cardiac disease, diabetes, hypertension and obesity with the distinctive outlook of amalgamating technology with traditional healing of Ayurveda. Its approach to treatment using non-invasive, multidisciplinary and innovative therapies which has helped establish the Company as a dependable option for treating the chronic ailments.

The Company is primarily engaged in research and development in ayurvedic medicines and the sale of ayurvedic medicines & products through its various franchises and own clinics. The Company is also engaged in providing Ayurvedic medical professional services across its various clinics including panchkarma and other ayurvedic treatments through running of ayurvedic Hospital.

The Healthcare industry in India comprises of hospitals, medical devices, clinical trials, outsourcing, tele medicine, medical tourism, health insurance, and medical equipment. The Company is a health care provider primarily in the India's chronic care ecosystem. The Company provide healthcare services through Madhavbaug clinics. It operate 302 clinics across Maharashtra, Madhya Pradesh, Gujarat, Uttar Pradesh, Kerala, Goa, Chhattisgarh and Karnataka. Out of these 49 are company owned, 57 are OPD's and 196 are franchise clinics. The Company also operate two cardiac prevention and rehabilitation hospitals in Khopoli and Kondhali respectively. Currently, the Company has a network including 302 Clinics and 2 Fully equipped Hospital.

The Company has entered into MOU dated April 1, 2019 with Vaidya Sane's Ayurvedic Education And Agricultural Research Trust for the entire management, medical services and treatments being carried out at Khopoli Hospital. The Company use clinic based health care delivery model along with tele-medicine to ensure easy accessibility to patients. Apart from treatments, as a means of raising awareness about disease and its associated complications, the Company conduct a number of workshops, support events etc. with a singular objective of helping patients manage their chronic non-communicable conditions more effectively as well.

At Madhavbaug clinics and hospitals, the Company use modern diagnostics, diet and physiotherapy and advanced Ayurveda to provide Heart disease, Diabetes, Hypertension & Obesity reversal treatments to our patients. This helps in improving the exercise tolerance of patients - improvement in grade of symptoms, improvement in maximum oxygen uptake, reduction in Hba1c, and metabolic equivalents (METs).

In 2006, First Cardiac Prevention and Rehabilitation Hospital was set up at Khopoli and inaugurated opening of first Madhavbaug Clinic at Dombivili, Maharashtra.

In 2009, the Company established in house research and development team at Thane.

In 2012, the Company established the First Cardiac Prevention and Rehabilitation Hospital at Nagpur.

In 2013, the Company inaugurated opening of 100th Madhavbaug Clinic at Kankavli, in Ratnagiri.

In 2014, the Company launched Arogyam Hriday Sampada with a Mission to create awareness of heart disease.

In 2015, the Company launched therapies for risk factors such as diabetes, obesity and hypertension at Madhavbaug Clinics.

In 2016, the Company launched a research based disease wise diet kits at Madhavbaug Clinics for aiding healthcare programmes and established Madhavbaug Institute of Preventive Cardiology with MUHS. These kits aid in the recovery and rehabilitation of its patients.

In 2017, Madhavbaug Clinics received Frost and Sullivan's 2017 India Best Practices Award and the Company's randomized controlled trial by Madhavbaug was published in Indian Heart Journal, Official publication of Cardiological Society of India.

In 2018, Madhavbaug Clinics ventured into India Book of Records for conducting GTT of 661 diabetic patients in single day at 13 different locations. The Company participated as main sponsor of World Ayurved Congress 2018 held in Ahmedabad. Apart from this, the Company inaugurated the opening of 200th Madhavbaug Clinic at Nanded, in Maharashtra.

In 2019, Madhavbaug introduced research based heart blockage management program. The Company achieved new registrations of over 90,000 patients and more than 27,000 stress tests were conducted and over 3,00,000 panchakarma procedures performed.

In 2020, the Company launched MIB Pulse Mobile Application for patient engagement.

In 2021, the Company inaugurated the opening of 250th Madhavbaug Clinic at Vashi. The Company's conducted Research trial on one year follow-up of diabetes patients treated by Madhavbaug was published in Journal of Association of Physicians of India. The Company achieved MIB Pulse Mobile Application over 1,00,000 downloads, which was developed by a third-party vendor. It calculated the risk of getting a heart attack by considering risk factors that a person has and also gave tips on how to reduce & manage the risk.

The Company has also launched online portal 'www.madhavbaugwellness.com' for new wellness products such as Madhav Shakti
Atta, apple cider vinegar, prosix dosa mix, nutriboom ghavan mix, digy smooth moong daliya, lentigrain idli mix, Insta health thalli peeth, power mix muthiya aata, diaphragm kadha, arj kadha, groundnut oil, amla lichi syrup, etc. and many more.

The Company made a public issue of 27,71,200 Equity Shares by raising funds aggregating to Rs. 20.22 Crore in February, 2022.

In 2022-23, the Company incorporated F- Health Accelerators Private Limited as a Subsidiary Company. It further formed its Company in the name of 'Madhavbaug Health Food Supplements Trading Co. LLC' for awareness of Ayurveda at International Level in Dubai. In April 2023, the Company executed share purchase agreement with shareholders of Dynamic Remedies Private Limited and UV Ayurgen Pharma Private Limited to buy 100% equity share capital making them a wholly owned subsidiary of Company.

The Company has inked a Memorandum of Understanding (MOU) with Raja Ramdeo Anandilal Podar Central Ayurveda Research Institute (RRAPCARI) to undertake a research project entitled as 'Efficacy of Ayurvedic interventions (Hridyarnava Rasa and Harityakadi Yoga) as an add-on to standard care in Stable Coronary Artery Disease (CAD) assessed through Global Longitudinal Strain Imaging Technique (GLSIT)-A Randamised Controlled Trial' in 2023-24.

Parent organization Indian Private
NSE symbol MADHAVBAUG
Founded 1999
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Vaidya Sane Ayurved Laboratories Ltd?

Answer Field

The share price of Vaidya Sane Ayurved Laboratories Ltd for NSE is ₹ 125 and for BSE is ₹ 0.00.

What is the Market Cap of Vaidya Sane Ayurved Laboratories Ltd?

Answer Field

The market cap of Vaidya Sane Ayurved Laboratories Ltd for NSE is ₹ 1,31.41 Cr. and for BSE is ₹ 0.0 Cr. as of now.

What is the 52 Week High and Low of Vaidya Sane Ayurved Laboratories Ltd?

Answer Field

The 52 Week High and Low of Vaidya Sane Ayurved Laboratories Ltd for NSE is ₹ 200.00 and ₹ 81.10 and for BSE is ₹ 0.00 and ₹ 0.00.

How to Buy Vaidya Sane Ayurved Laboratories Ltd share?

Answer Field

You can trade in Vaidya Sane Ayurved Laboratories Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Vaidya Sane Ayurved Laboratories Ltd?

Answer Field

The 1 year returns on the stock has been -36.82%.

What is the Current Share Price of Vaidya Sane Ayurved Laboratories Ltd?

Answer Field

Vaidya Sane Ayurved Laboratories Ltd share price is for NSE ₹ 125 & for BSE ₹ 0.00 as on Apr 30 2025 02:28 PM.

What is the Market Cap of Vaidya Sane Ayurved Laboratories Ltd Share?

Answer Field

The market cap of Vaidya Sane Ayurved Laboratories Ltd for NSE ₹ 1,31.41 & for BSE ₹ 0.0 as on Apr 30 2025 02:28 PM.

What is the P/E Ratio of Vaidya Sane Ayurved Laboratories Ltd Share?

Answer Field

As on Apr 30 2025 02:28 PM the price-to-earnings (PE) ratio for Vaidya Sane Ayurved Laboratories Ltd share is 126.26.

What is the PB ratio of Vaidya Sane Ayurved Laboratories Ltd Share?

Answer Field

As on Apr 30 2025 02:28 PM, the price-to-book (PB) ratio for Vaidya Sane Ayurved Laboratories Ltd share is 39.56.

How to Buy Vaidya Sane Ayurved Laboratories Ltd Share?

Answer Field

You can trade in Vaidya Sane Ayurved Laboratories Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Vaidya Sane Ayurved Laboratories Ltd Share on Bajaj Broking App?

Answer Field

To buy Vaidya Sane Ayurved Laboratories Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Vaidya Sane Ayurved Laboratories Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|